Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

July 28, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
July 6, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
June 28, 2022

Immunic to Participate in Industry and Scientific Conferences in July
June 15, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
June 8, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
June 2, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
May 10, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
May 3, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
April 25, 2022

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

Show per page